First Patient Dosed in New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialysis Patients The first patient has been treated in a unique clinical trial to evaluate the safety and efficacy of a novel pharmacologic intervention…
Skeyeon Secures Key Patent for Very-Low Earth Orbit Satellite Constellations with Onboard Imaging and Direct-to-Ground Data Delivery Enabling Near-Real-Time Earth Observation Skeyeon, Inc., today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,559,451 B2,…
Artis BioSolutions Establishes U.S.-based Synthetic DNA Manufacturing Hub in Boston Artis BioSolutions an advanced therapies company dedicated to integrating the specialized technologies, infrastructure, and manufacturing capabilities required to deliver next-generation genetic medicines, today announced the establishment of new synthetic DNA…
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on…
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026 Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced partner…
Sakura Finetek Global and Hamamatsu Photonics K.K. Global Alliance Press Release Sakura Finetek Global, a worldwide leader in automated tissue and slide preparation solutions for anatomic pathology, and Hamamatsu Photonics K.K., a global leader in imaging technologies, today announced an…
California Public Utilities Commission Conditionally Approves RNG Procurement Contract from Anaergia’s SoCal Biomethane Facility Anaergia Inc. (“Anaergia” or the “Company”) (TSX: ANRG; OTCQX: ANRGF) reports that the California Public Utilities Commission (“CPUC”) has conditionally approved a long-term biomethane procurement contract…
The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ® The 15-20 National Hospital (l’Hôpital national des 15-20) in Paris and GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME…
Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review Ionis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for zilganersen, an…
Biocytogen Announces Strategic Collaboration with Moonlight Bio to Advance Cell Therapies Using Library of Antibody Binders Biocytogen Pharmaceuticals a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, announced a strategic collaboration with…
ClearNote Health Appoints Jeffrey Venstrom, MD, as Chief Medical Officer and Expands Leadership Team to Drive Clinical Adoption of Early Cancer Detection Tests ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced…
iECURE Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of ECUR-506 Ahead of Planned BLA Submission iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic in vivo targeted gene insertion therapies for the treatment…